

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Alogliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 07, 2019
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Alogliptin Benzoate,Pioglitazone
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Teijin Pharma
Deal Size : $1,250.0 million
Deal Type : Divestment
Takeda Completes Sale of Four Diabetes Products in Japan to Teijin Pharma Limited
Details : The portfolio divested to Teijin Pharma was comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.
Product Name : Liovel
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 01, 2021
Lead Product(s) : Alogliptin Benzoate,Pioglitazone
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Teijin Pharma
Deal Size : $1,250.0 million
Deal Type : Divestment

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Teijin Pharma
Deal Size : $1,250.0 million
Deal Type : Divestment
Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited
Details : The portfolio to be divested to Teijin Pharma is comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.
Product Name : Liovel
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 26, 2021
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Teijin Pharma
Deal Size : $1,250.0 million
Deal Type : Divestment

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Celltrion
Deal Size : $278.0 million
Deal Type : Divestment
Takeda to Divest Select APAC Assets to Celltrion for $278M
Details : The portfolio to be divested to Celltrion includes a variety of OTC products and pharmaceutical products such as Nesina® and Edarbi® and Products in a variety of indications.
Product Name : Liovel
Product Type : Miscellaneous
Upfront Cash : $266.0 million
June 11, 2020
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Celltrion
Deal Size : $278.0 million
Deal Type : Divestment

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Alogliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 18, 2018
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus
Details : Alogliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 03, 2017
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 Alogliptin Pediatric Study
Details : Alogliptin Benzoate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 04, 2016
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Takeda Pharmaceutical | Kyung Hee University Hospital at Gangdong | Bucheon St. Mary's Hospital | Korea University Guro Hospital | Ajou University School of Medicine | Inha University | Kangbuk Samsung Hospital | Seoul Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Function
Details : Alogliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 06, 2016
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Takeda Pharmaceutical | Kyung Hee University Hospital at Gangdong | Bucheon St. Mary's Hospital | Korea University Guro Hospital | Ajou University School of Medicine | Inha University | Kangbuk Samsung Hospital | Seoul Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Kun-Ho Yoon
Deal Size : Inapplicable
Deal Type : Inapplicable
An Extension Study of PEAK Trial
Details : Alogliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 05, 2016
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Kun-Ho Yoon
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Bioavailability Study of SYR-322MET
Details : Alogliptin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 24, 2015
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable



